

November 7, 2023

Baird Global Industrial Conference



Disclaimer

Forward-Looking Statements

This presentation and the accompanying oral commentary (this “presentation”) contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,” “might,” “should,” “would,” “will,” “understand” and similar words are intended to identify forward looking statements. These forward-looking statements include but are not limited to, statements regarding our future operating results and financial position, our business strategy and plans, our objectives for future operations, macroeconomic trends, foreign exchange, interest rate and inflation expectations, any future mergers, acquisitions, divestitures and strategic investments, including the completion and integration of previously completed transactions, our future share capitalization and any exercise, exchange or other settlement of our outstanding warrants and other securities. There are a significant number of factors that could cause actual results to differ materially from statements made in this presentation, including changes in domestic and foreign business, market, economic, financial, political and legal conditions, especially related to matters affecting Russia, the relationship between the United States and China and conflict in the Middle East; risks related to the public’s perception of nuclear radiation and nuclear technologies; risks related to the continued growth of our end markets; our ability to win new customers and retain existing customers; our ability to realize sales expected from our backlog of orders and contracts; risks related to governmental contracts; our ability to mitigate risks associated with long-term fixed price contracts, including risks related to inflation; risks related to information technology disruption or security; risks related to the implementation and enhancement of information systems; our ability to manage our supply chain or difficulties with third-party manufacturers; risks related to competition; our ability to manage disruptions of, or changes in, our independent sales representatives, distributors and original equipment manufacturers; our ability to realize the expected benefit from strategic transactions, such as acquisitions, divestitures and investments, including any synergies, or internal restructuring and improvement efforts; our ability to issue debt, equity or equity-linked securities in the future; risks related to changes in tax law and ongoing tax audits; risks related to future legislation and regulation both in the United States and abroad; risks related to the costs or liabilities associated with product liability claims; our ability to attract, train and retain key members of our leadership team and other qualified personnel; risks related to the adequacy of our insurance coverage; risks related to the global scope of our operations, including operations in international and emerging markets; risks related to our exposure to fluctuations in foreign currency exchange rates, interest rates and inflation, including the impact on our debt service costs; our ability to comply with various laws and regulations and the costs associated with legal compliance; risks related to the outcome of any litigation, government and regulatory proceedings, investigations and inquiries; risks related to our ability to protect or enforce our proprietary rights on which our business depends or third-party intellectual property infringement claims; liabilities associated with environmental, health and safety matters; our ability to predict our future operational results; risks associated with our limited history of operating as an independent company; and the effects of health epidemics, pandemics and similar outbreaks may have on our business, results of operations or financial condition. Further information on risks, uncertainties and other factors that could affect our financial results are included in the filings we make with the Securities and Exchange Commission (the “SEC”) from time to time, including our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other periodic reports filed or to be filed with the SEC.

You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Basis of Presentation

As a result of the business combination (the “Business Combination”) between Mirion Technologies (TopCo), Ltd. and GS Acquisition Holdings Corp II (“GSAH”), the Company’s financial statement presentation distinguishes Mirion TopCo as the “Predecessor” until the closing date of the Business Combination, October 20, 2021 (the “Closing Date”). Mirion Technologies, Inc. (“Mirion” or the “Company”), which includes the combination of Mirion TopCo and GSAH subsequent to the Business Combination, is the “Successor” for periods starting from the Closing Date. As a result of the application of the acquisition method of accounting in the Successor period, the financial statements for the Successor period are presented on a full step-up basis as a result of the Business Combination, and are therefore not comparable to the financial statements of the Predecessor period that are not presented on the same full step-up basis due to the Business Combination.

Non-GAAP Financial Measures

In addition to our results determined in accordance with GAAP, we believe non-GAAP measures are useful in evaluating our operating performance, including Adjusted Revenue, Organic Revenue, Adjusted Gross Profit, Adjusted EBITDA, Adjusted EPS, Adjusted Free Cash Flow, Adjusted Net Income, Organic Order Growth and Net Leverage. We use this non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. See the footnotes on the slides where these measures are discussed and the Non-GAAP reconciliations in the Appendix for a description of these non-GAAP financial measures and reconciliations to the most directly comparable GAAP financial measures. Additionally, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control or cannot be reasonably predicted. Accordingly, a reconciliation for our guidance for Organic Revenue Growth, Adjusted EBITDA, Adjusted EPS, Adjusted Free Cash Flow and Net Leverage is not available without unreasonable effort.

Industry and Market Data


In this presentation, we rely on and refer to information and statistics regarding market participants in the sectors in which Mirion competes and other industry data. We obtained this information and statistics from third-party sources, including reports by market research firms and company filings. Mirion has not independently verified the data obtained from these sources and cannot assure you of the data’s accuracy or completeness.

MIRION MISSION

To harness our unrivaled knowledge of ionizing radiation for the greater good of humanity

With safety at the core of our solutions, Mirion:

- Enables safer production of nuclear power, supporting global energy production and carbon neutrality
- Provides a safer working environment for medical professionals
- Assists patients to obtain the life-saving treatments they need
- Helps protect heroes on the front-lines



Strong Leadership Founded on Innovation & Scale

 MIRION
CREATED
2005

130+
PATENTS¹

#1 POSITION
IN 15 OF 18
PRODUCT CATEGORIES

700+
UNIQUE
PRODUCTS

OPERATIONS
SPAN ACROSS
12 COUNTRIES

20-50 YEAR
CUSTOMER
RELATIONSHIPS²

350+
ENGINEERS
& PHYSICISTS

2,800
EMPLOYEES

Investment Thesis



Global industry innovation leader in ionizing radiation safety supported by unmatched scale



High visibility into long term **recurring revenue growth**



Delivers safety and **compulsory products** to **blue chip customer** profile at **attractive margins**



Resilient business model through varying economic cycles



Committed to driving success through **operational excellence**



Diversified product portfolio with vertical flexibility




Strong competitive moat strengthened by **technology-focused innovation**



Disciplined capital allocation focused on generating shareholder value

Medical Segment Overview

CY22 Medical Revenue¹



RADIATION THERAPY QUALITY ASSURANCE

Premium Category Leadership

100% of the **Top 100 Cancer
Centers** in the US

~**80%** of Cancer
Centers World-Wide

NUCLEAR MEDICINE

Global Leader in Chosen Categories

Dose Calibration

Thyroid Uptake Systems

Well Counters

Lung Ventilation Systems

DOSIMETRY


Technology & Innovation Focused

#2 Player in the US Market
With >3x Revenue of The
Next Nearest Competitor

Growth Opportunity in
European Market

Technologies Segment Overview

CY22 Technologies Revenue¹



NUCLEAR POWER

High Visibility to Revenue Opportunity and High Degree of Stickiness

Installed Base **Covers ~90% of Reactors** Worldwide

Revenue Opportunity of **~\$60-\$120M** Over Entire Lifecycle of Plant

DEFENSE & DIVERSIFIED



MILITARY DEFENSE



CIVIL DEFENSE

Underlying Long Standing Value Coupled with Growth Opportunity

Consistently the **Top or Amongst the Top 3** Players Globally

Attractive and Achievable Market Share Growth



LABS & RESEARCH

Diversified, Innovative Product Portfolio Drives Recurring Revenue

Deep and long-standing relationships with blue chip customer base

Preferred provider to leading research facilities

Innovation driving advancements across our portfolio

Acquisition of ec² Software Solutions

- Closed acquisition of ec² Software Solutions LLC and NUMA LLC (collectively “ec²”) on November 1st, 2023
- ec² is a leading provider of end-to-end nuclear medicine workflow software; adds strategic software capability to Mirion’s Nuclear Medicine portfolio, expanding overall software solutions

Company Overview:

- ec² designs, implements and supports comprehensive software solutions to simplify the daily operations of nuclear medicine facilities
- Its technology and expertise is used to:
 - Keep track of inventory, doses, patient information and billing
 - Streamline treatment and diagnostic process
 - Relieve the burden of patient reporting in outpatient facilities
- ec²’s solutions service the nuclear medicine, molecular imaging, nuclear pharmacy and PET manufacturing fields



- Purchase Price¹: \$33M (all cash)
- CY 2023 Estimates²
 - Revenue: ~\$12M
 - Proforma Adjusted EBITDA: ~\$5.5M
- Headquarters: Las Vegas, NV
- 50+ employees (~25 software engineers)

1) 5% of purchase price will be paid in deferred payment to seller within the next 12 calendar months.

2) Inclusive of pre-acquisition financial results.

Q3 Earnings Recap

- Organic order growth of ~46% compared to Q3 2022; 5th consecutive quarter of backlog expansion, record backlog position highlighted by nuclear new build and spare parts orders
- Consolidated Q3 2023 organic revenue growth of +17.3%; Medical +5.2% and Technologies +26.3%
- Adjusted EBITDA margin expanded by 120 bps; expansion in both segments
- Adjusted Free Cash Flow of \$17.2M in Q3 2023; net leverage¹ at 3.4x; Net working capital was a source of \$8.6M of cash in Q3
- Reiterated 2023 guidance²; organic growth of 6% - 8%; Adjusted EBITDA of \$175M - \$185M; Adjusted Free Cash Flow of \$45M - \$75M
- Expecting 3.1x net leverage by year-end, inclusive of ec² acquisition

1) Net leverage defined as total net debt divided by M&A Adjusted EBITDA.

2) Guidance as of November 1, 2023.

Appendix

Significant Leverage to Key End Market Trends

TECHNOLOGIES



Higher Natural
Gas Prices



Consistent
Replacement
Cycle



Stricter
Environmental
Regulations



Desire for Energy
Independence



Prioritization of
Nuclear Threat
Prevention



Nuclear
Research



Carbon
Neutrality



Robust
Government
Support



Growth in Defense &
Diversified Activity

MEDICAL



Rising Prevalence
of Cancer and
Treatments



Growing
Install Base



Aging Global
Population



Focus on
Healthcare
Personnel Safety



Increased
Regulatory
Standards



Increased Prevalence
of Radiation
Therapy/Diagnosis



Growing Middle
Class Across
the Globe



Developing Nations
Seeking 1st World
Quality Healthcare




Technology
Adoption for
Adjacent Uses

Medical Value-Added Solutions

Diversified product portfolio in resilient end markets.
Supported by aging population and growing global middle class.

CY22 Mirion Revenue¹



PRODUCT CATEGORIES

Cancer Diagnostics & Therapy QA



Occupational Dosimetry Services



Nuclear Medicine



Medical Imaging



KEY CUSTOMER GROUPS



Hospitals



Clinics / Urgent Care



Dental Offices



Oncology Departments



Veterinary Offices




OEM for RT



Technologies Value-Added Solutions

Technology leadership, rigorous regulatory requirements, and demanding design all contribute to high barriers of entry.

CY22 Mirion Revenue¹



PRODUCT CATEGORIES

Laboratory & Scientific Analysis Systems



Radiation Measurement & Health Physics Instrumentation



Search & Radiological Security Systems



Radiation Monitoring Systems



Radiation Instrumentation and Controls



KEY CUSTOMER GROUPS



Militaries



Federal Agencies



Airports



Nuclear/SMR OEM's



Universities



Police Departments



Laboratories and Research Facilities



Utilities



Nuclear Power: An Essential Source of Green Energy

Our View: The world cannot achieve carbon neutrality goals without wide proliferation of nuclear power

Our Role: Mirion services all stages of a plant's lifecycle and is technology-agnostic across nuclear OEMs; solutions are key to the safety of personnel and materials from radiation and ensuring effective operation

Positive Outlook | Nuclear market conditions strongest in decades

- *Global push for carbon neutrality to be a key growth factor going forward in medium- and longer-term horizon*
- *Desire for energy independence, re-shoring trends*
- *Robust government support for reliable and diverse supply of energy sources, enabling nuclear re-investment and new builds*
- *Higher gas prices supporting better economics for existing nuclear fleet and higher capacity requirements*

Illustrative Revenue Opportunity For Mirion Across Traditional NPP Cycle

Typical revenue profile assuming 60-year operational life




SMRs: The Future of Nuclear Power

- Game-changing development in the nuclear space to replace coal plants
- Growing opportunity for Mirion
- Establishing relationships across population of SMR designers
- Mirion's solutions will remain OEM and design agnostic

Record of Driving Value Through M&A

Select Transactions Completed Since 2016



Mirion's success reflects effective M&A over 15+ years

Active M&A function with talent and capabilities to pursue large transactions

~\$200-\$250M Revenue Acquisition of Canberra

Institutional knowledge for identifying, acquiring, and integrating targets

~\$400M Sales Generated via M&A Since 2016



Proven and consistent track record delivering on synergy capture

Broad Product Portfolio Addresses Attractive End Markets

MARKET LEADERSHIP

CATEGORY	BU	END MARKET(S)
Radiation Monitoring Systems	Technologies	
Reactor Instrumentation & Controls	Technologies	
Imaging Systems for Extreme Environments	Technologies	 
NDA, Waste Measurement & Criticality Systems	Technologies	 
Physical & Cyber Security Systems	Technologies	
Gamma Spectroscopy Detector Systems	Technologies	  
Alpha Spectroscopy Instruments	Technologies	
Alpha/Beta Counting Instruments	Technologies	 
Research, Education & Industrial Solutions	Technologies	
Contamination & Clearance Monitors	Technologies	 
Portable Radiation Measurement	Technologies	 
Military Radiation Measurement Instruments	Technologies	
Active Dosimetry & Telemetry Systems	Technologies Medical	   
Cancer Diagnostics & Therapeutics QA	Medical	
Nuclear Medicine	Medical	
Occupational Dosimetry Services	Medical	

FRAGMENTED

CATEGORY	BU	END MARKET
Medical Imaging	Medical	
Security & Search Systems	Technologies	



Nuclear Power



Labs & Research



Defense & Diversified



Occupational Dosimetry



RT QA



Nuclear Medicine

ESG is Integrated into Mirion's Mission

Mirion's ESG Policies, Programs & Initiatives serve to support our mission of harnessing our unrivaled knowledge of ionizing radiation for the greater good of humanity.



Environment

Our solutions protect **people, property,** and the **environment** from harmful effects of ionizing radiation

Our work enables **safer production** of nuclear power, supporting **global energy production** and **carbon neutrality**



Social

Provide a **safer working environment** for employees and customers by maintaining the **highest quality** product safety standards

Offer products that **advance** medical professionals' ability to **detect and treat** injuries and diseases

Commitment to human and labor rights ensures that **strong ethical standards** are practiced throughout our organization and supply chain

Empower and **enrich** our diverse workforce through mentoring and leadership programs, diversity trainings, and promoting employee development as we **hire** and **retain talented teams**



Governance

Board oversight of ESG underscores Mirion's commitment to **ESG initiatives** as a key business priority

Strong ethics and **compliance standards** reduce organizational risk and **protect** our reputation

Committed to Responsible and Sustainable Operations

We recognize ESG as a fundamental piece to our future success



We are in the early stages of our ESG journey as a public company. **We are committed to advancing our ESG initiatives and will rely on the input from global stakeholders and regulatory agencies to guide future priorities.**

RECENT ACCOMPLISHMENTS:

Integration of ESG best practices into our Corporate Governance:

- ✓ ESG oversight including climate related risks and cybersecurity
- ✓ Requiring skills and expertise for our Board to include ESG and cybersecurity

Developed formal policies and programs including:

- ✓ Supplier Code of Conduct
- ✓ Whistleblower

Initiated conversations and reports with ESG rating agencies



CURRENT EFFORTS:

- ✓ Working to publish our inaugural Sustainability Report with SASB-aligned disclosure
- ✓ Conducting an initial energy audit to create a roadmap for future scope 1 and 2 emissions inventory



FUTURE GOALS:

- ✓ **Establish** concrete ESG targets to measure ESG progression
- ✓ **Showcase** improvement in ESG ratings
- ✓ **Enhance** public ESG disclosures

Non-GAAP Reconciliations

Non-GAAP Reconciliations

Organic Order Growth

	<i>a</i>	<i>b</i>	<i>a - b = c</i>	<i>c / b = d</i>
	Thee Months Ended	Thee Months Ended		
(\$ in millions)	September 30, 2023	September 30, 2022	Variance (\$)	Variance (%)
Total Orders	261.1	180.9	80.2	44.3%
Adjustment for SIS Acquisition	-1.9	0		
Adjustment for Biodex Divestiture	0	-3.6		
Organic Orders	259.2	177.3	81.9	46.2%

Eleven Quarter Segment Reconciliation

Medical

(\$ in millions)	Successor							Combined (non-GAAP)	Predecessor		
	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021
Revenue	\$ 68.8	\$ 68.0	\$ 66.4	\$ 76.1	\$ 68.7	\$ 66.8	\$ 60.1	\$ 57.5	\$ 52.0	\$ 52.1	\$ 51.5
Revenue reduction from purchase accounting	—	—	—	—	—	—	—	3.1	3.7	3.7	4.3
Adjusted Revenue	\$ 68.8	\$ 68.0	\$ 66.4	\$ 76.1	\$ 68.7	\$ 66.8	\$ 60.1	\$ 60.6	\$ 55.7	\$ 55.8	\$ 55.8
YoY % Growth - Total	0.1 %	1.8 %	10.5 %	25.4 %	23.3 %	19.6 %	7.7 %	91.2 %	173.0 %	204.9 %	269.5 %
YoY % Growth - Organic	5.2 %	6.9 %	10.8 %	23.6 %	20.7 %	15.1 %	0.7 %	0.2 %	10.8 %	0.1 %	3.1 %
YoY % Growth - Acquisitions	(5.8)%	(5.2)%	— %	2.8 %	4.4 %	5.8 %	7.7 %	91.6 %	162.3 %	202.2 %	264.0 %
YoY % Growth - FX	0.7 %	0.1 %	(0.3)%	(1.0)%	(1.8)%	(1.3)%	(0.6)%	(0.6)%	— %	2.6 %	2.4 %
Income (Loss) from Operations	\$ 4.0	\$ (3.1)	\$ 0.7	\$ (86.6)	\$ (3.3)	\$ (2.2)	\$ (6.7)	n.m	\$ 0.3	\$ (2.4)	\$ (2.9)
Amortization	13.5	13.7	13.9	14.7	15.3	17.0	17.3	n.m	8.0	8.9	8.3
Depreciation - core	4.1	3.6	3.9	3.7	3.5	3.5	2.6	n.m	2.8	3.9	2.5
Depreciation - Mirion Business Combination step-up	1.2	1.2	1.2	1.2	1.2	1.2	1.2	n.m	—	—	—
Revenue reduction from purchase accounting	—	—	—	—	—	—	—	n.m	3.7	3.7	4.3
Stock compensation	0.2	0.2	0.1	0.2	0.1	0.2	0.1	n.m	—	—	—
Cost of revenue impact from purchase accounting	—	—	—	—	—	—	0.9	n.m	—	—	4.7
Goodwill impairment	—	—	—	87.3	—	—	—	n.m	—	—	—
Non-operating expenses	0.6	6.7	0.6	5.4	3.8	2.1	3.2	n.m	2.3	2.1	0.6
Other income/expense	(0.1)	—	—	(0.4)	(0.1)	0.4	—	n.m	—	(0.1)	—
Adjusted EBITDA	\$ 23.5	\$ 22.3	\$ 20.4	\$ 25.4	\$ 20.4	\$ 22.2	\$ 18.6	\$ 19.7	\$ 17.1	\$ 16.0	\$ 17.5
Income from operations as a % of Revenue	5.8 %	(4.6)%	1.1 %	(113.8)%	(4.8)%	(3.3)%	(11.1)%	n.m.	0.6 %	(4.6)%	(5.6)%
Adjusted EBITDA as a % of Adjusted Revenue	34.2 %	32.8 %	30.7 %	33.4 %	29.7 %	33.2 %	30.9 %	32.5 %	30.7 %	28.7 %	31.3 %

Eleven Quarter Segment Reconciliation

Technologies

(\$ in millions)	Successor							Combined (non-GAAP)	Predecessor		
	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021
Revenue	\$ 122.4	\$ 129.2	\$ 115.7	\$ 141.8	\$ 92.2	\$ 109.0	\$ 103.1	\$ 120.3	\$ 92.3	\$ 127.9	\$ 114.7
Revenue reduction from purchase accounting	—	—	—	—	—	—	—	—	—	—	—
Adjusted Revenue	\$ 122.4	\$ 129.2	\$ 115.7	\$ 141.8	\$ 92.2	\$ 109.0	\$ 103.1	\$ 120.3	\$ 92.3	\$ 127.9	\$ 114.7
YoY % Growth - Total	32.8 %	18.5 %	12.2 %	17.9 %	(0.1)%	(14.7)%	(10.2)%	1.1 %	(2.0)%	4.0 %	21.1 %
YoY % Growth - Organic	26.3 %	9.3 %	6.1 %	16.8 %	2.0 %	(9.0)%	(6.6)%	3.3 %	(2.4)%	(0.2)%	15.6 %
YoY % Growth - Acquisitions	2.7 %	8.2 %	9.1 %	8.2 %	6.0 %	— %	— %	— %	— %	— %	— %
YoY % Growth - FX	3.8 %	1.0 %	(3.0)%	(7.1)%	(8.1)%	(5.7)%	(3.6)%	(2.2)%	0.4 %	4.2 %	5.5 %
Income (Loss) from Operations	\$ 5.4	\$ 12.8	\$ 5.5	\$ (50.8)	\$ (3.3)	\$ (46.5)	\$ (2.5)	n.m	\$ 10.1	\$ 26.6	\$ 10.8
Amortization	19.2	19.5	19.7	19.6	19.9	20.5	21.5	n.m	8.1	9.7	10.3
Depreciation - core	2.2	2.2	2.2	2.3	2.1	1.9	1.9	n.m	2.1	2.6	2.4
Depreciation - Mirion Business Combination step-up	0.3	0.3	0.3	0.3	0.3	0.4	0.4	n.m	—	—	—
Revenue reduction from purchase accounting	—	—	—	—	—	—	—	n.m	—	—	—
Stock compensation	0.3	0.3	0.2	0.3	0.3	0.3	0.1	n.m	—	—	—
Cost of revenue impact from purchase accounting	—	—	—	—	—	—	5.4	n.m	—	—	—
Goodwill impairment	—	—	—	69.3	—	55.2	—	n.m	—	—	—
Non-operating expenses	0.3	0.2	0.6	1.9	0.8	1.2	1.1	n.m	2.4	3.3	7.0
Other income/expense	—	(0.1)	—	(0.1)	0.1	—	—	n.m	—	0.1	—
Adjusted EBITDA	\$ 27.7	\$ 35.2	\$ 28.5	\$ 42.8	\$ 20.2	\$ 33.0	\$ 27.9	\$ 35.1	\$ 22.7	\$ 42.3	\$ 30.6
Income from operations as a % of Revenue	4.4 %	9.9 %	4.8 %	(35.8)%	(3.6)%	(42.7)%	(2.4)%	n.m.	10.9 %	20.8 %	9.5 %
Adjusted EBITDA as a % of Adjusted Revenue	22.6 %	27.2 %	24.6 %	30.2 %	21.9 %	30.3 %	27.1 %	29.2 %	24.6 %	33.1 %	26.7 %

Eleven Quarter Segment Reconciliation

Corporate & Other

(\$ in millions)	Successor							Combined (non-GAAP)	Predecessor		
	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021
Revenue	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
Revenue reduction from purchase accounting	—	—	—	—	—	—	—	—	—	—	—
Adjusted Revenue	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
Income (Loss) from Operations	\$ (20.5)	\$ (20.3)	\$ (19.8)	\$ (24.5)	\$ (21.0)	\$ (25.9)	\$ (24.4)	n.m	\$ (19.3)	\$ (19.4)	\$ (16.8)
Amortization	—	—	—	—	—	—	—	n.m	—	—	—
Depreciation - core	—	0.2	0.1	0.3	0.2	0.2	0.1	n.m	0.2	0.3	0.2
Depreciation - Mirion Business Combination step-up	0.1	0.1	0.1	—	0.1	0.1	—	n.m	—	—	—
Revenue reduction from purchase accounting	—	—	—	—	—	—	—	n.m	—	—	—
Stock compensation	5.6	5.5	5.3	6.5	8.1	8.0	7.6	n.m	—	—	(0.1)
Cost of revenue impact from purchase accounting	—	—	—	—	—	—	—	n.m	—	—	—
Goodwill impairment	—	—	—	—	—	—	—	n.m	—	—	—
Non-operating expenses	2.7	1.2	1.9	5.7	2.5	5.0	5.1	n.m	10.3	10.2	8.4
Other income/expense	(0.3)	0.1	0.1	—	0.2	(0.1)	—	n.m	(0.1)	0.5	0.2
Adjusted EBITDA	\$ (12.4)	\$ (13.2)	\$ (12.3)	\$ (12.0)	\$ (9.8)	\$ (12.6)	\$ (11.6)	\$ (10.0)	\$ (8.9)	\$ (8.4)	\$ (8.2)
Income from operations as a % of Revenue	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a
Adjusted EBITDA as a % of Adjusted Revenue	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.

Eleven Quarter Segment Reconciliation

Consolidated

(\$ in millions)	Successor							Combined (non-GAAP)	Predecessor		
	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021
Revenue	\$ 191.2	\$ 197.2	\$ 182.1	\$ 217.9	\$ 160.9	\$ 175.8	\$ 163.2	\$ 177.8	\$ 144.3	\$ 180.0	\$ 166.2
Revenue reduction from purchase accounting	—	—	—	—	—	—	—	3.1	3.7	3.7	4.3
Adjusted Revenue	\$ 191.2	\$ 197.2	\$ 182.1	\$ 217.9	\$ 160.9	\$ 175.8	\$ 163.2	\$ 180.9	\$ 148.0	\$ 183.7	\$ 170.5
YoY % Growth - Total	18.8 %	12.2 %	11.6 %	20.5 %	8.7 %	(4.3)%	(4.3)%	20.0 %	29.1 %	29.9 %	55.3 %
YoY % Growth - Organic	17.3 %	8.4 %	7.9 %	19.1 %	9.0 %	(1.7)%	(4.2)%	2.7 %	(0.1)%	(0.2)%	14.0 %
YoY % Growth - Acquisitions	(1.0)%	3.1 %	5.7 %	6.4 %	5.4 %	1.8 %	2.5 %	19.3 %	28.9 %	26.1 %	36.3 %
YoY % Growth - FX	2.5 %	0.7 %	(2.0)%	(5.0)%	(5.7)%	(4.4)%	(2.6)%	(2.0)%	0.3 %	4.0 %	5.0 %
Income (Loss) from Operations	\$ (11.1)	\$ (10.6)	\$ (13.6)	\$ (161.9)	\$ (27.6)	\$ (74.6)	\$ (33.6)	n.m	\$ (8.9)	\$ 4.8	\$ (8.9)
Amortization	32.7	33.2	33.6	34.3	35.2	37.5	38.8	n.m	16.1	18.6	18.6
Depreciation - core	6.3	6.0	6.2	6.3	5.8	5.6	4.6	n.m	5.1	6.8	5.0
Depreciation - Mirion Business Combination step-up	1.6	1.6	1.6	1.5	1.6	1.7	1.6	n.m	—	—	—
Revenue reduction from purchase accounting	—	—	—	—	—	—	—	n.m	3.7	3.7	4.3
Stock compensation	6.1	6.0	5.6	7.0	8.5	8.5	7.8	n.m	—	—	(0.1)
Cost of revenue impact from purchase accounting	—	—	—	—	—	—	6.3	n.m	—	—	4.7
Goodwill impairment	—	—	—	156.6	—	55.2	—	n.m	—	—	—
Non-operating expenses	3.6	8.1	3.1	13.0	7.1	8.4	9.4	n.m	15.0	15.6	16.0
Other income/expense	(0.4)	—	0.1	(0.4)	0.2	0.3	—	n.m	(0.1)	0.5	0.2
Adjusted EBITDA	\$ 38.8	\$ 44.3	\$ 36.6	\$ 56.4	\$ 30.8	\$ 42.6	\$ 34.9	\$ 44.8	\$ 30.9	\$ 49.9	\$ 39.8
Income from operations as a % of Revenue	(5.8)%	(5.4)%	(7.5)%	(74.3)%	(17.2)%	(42.4)%	(20.6)%	n.m.	(6.2)%	2.7 %	(5.4)%
Adjusted EBITDA as a % of Adjusted Revenue	20.3 %	22.5 %	20.1 %	25.9 %	19.1 %	24.2 %	21.4 %	24.8 %	20.9 %	27.2 %	23.3 %

Non-GAAP Reconciliations

Adjusted Free Cash Flow

(\$ in millions)	Six Months Ended June 30, 2023	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2023
Net cash provided by (used for) operating activities	\$ 4.4	\$ 23.8	\$ 28.2
Purchases of property, plant and equipment and badges	(15.8)	(9.4)	(25.2)
Proceeds from derivative contracts	\$ 1.9	\$ 1.3	\$ 3.2
Free cash flow	\$ (9.5)	\$ 15.7	\$ 6.2
Non-operating cash flows	\$ 4.6	\$ 1.5	\$ 6.1
Adjusted free cash flow	\$ (4.9)	\$ 17.2	\$ 12.3

Non-GAAP Reconciliations

Net Leverage

<i>(dollars in millions)</i>	YTD22	YTD23
Ending cash balance	\$58	\$101
Debt from first lien term loan	824	695
Net Debt	\$766	\$594
LTM Adjusted EBITDA	153	176
LTM Adjusted EBITDA Contribution from M&A ¹	5	0
LTM Adjusted EBITDA Plus M&A Contribution	\$158	\$176
Total net debt / M&A Adjusted EBITDA (Net Leverage)	4.8x	3.4x